Shirish M. Gadgeel, MD, discusses the phase 1/2 ARROS-1 and ALKOVE-1 studies presented at the ESMO 2024 Congress. Researchers presented an updated safety and efficacy analysis at the ESMO 2024 Congress. The trial is evaluating perioperative pembrolizumab plus sacituzumab govitecan for certain patients with NSCLC. Dr. Li discusses important thoracic oncology data presented at the ESMO 2024 Congress, which was held in Barcelona, Spain Benjamin Besse, MD, PhD, shares insights from the research he presented as a late-breaking abstract at ESMO 2024. Martin Reck, MD, PhD, shares his insights on key data in lung cancer to be presented at the ESMO Congress 2024.